Study on the efficacy of Leptospira vaccines developed from serovars isolated from Trinidad and comparison with commercial vaccines using a hamster model

被引:21
作者
Suepaul, S. M. [1 ]
Carrington, C. V. [2 ]
Campbell, M. [1 ]
Borde, G. [1 ]
Adesiyun, A. A. [1 ]
机构
[1] Univ W Indies, Fac Med Sci, Sch Vet Med, St Augustine, Trinidad Tobago
[2] Univ W Indies, Fac Med Sci, Sch Med, St Augustine, Trinidad Tobago
关键词
Leptospira; Leptospirosis; Vaccine; Animal model; CANINE LEPTOSPIROSIS; INFECTION; IMMUNIZATION; PATHOGENESIS; VACCINATION; PROTECTION; VIRULENCE; ANTIGENS; GENE;
D O I
10.1016/j.vaccine.2010.06.019
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A hamster model was used to determine the efficacy of commercially prepared canine vaccines against Leptospira serovars circulating in Trinidad and to assess the effectivenes:. of killed whole-cell vaccines prepared from local isolates. The local isolates used for vaccine preparation and challenge were isolates of serovars Copenhageni and Mankarso obtained from a local dog and rodent. Their estimated lethal dose-50 (LD50) were 5 and 10 organisms, respectively and clinical signs observed on infection were consistent with leptospirosis An unvaccinated control group of hamsters and other groups of hamsters that had been vaccinated with 3 doses of (i) in-house whole-cell Copenhageni vaccine. (ii) in-house whole-cell Mankarso vaccine, (iii) commercial vaccine Brand A or (iv) commercial vaccines Brand B were challenged with 1000 times the LD50 of the respective challenge serovar. The most commonly used commercial vaccine (Brand A) did not offer protection to challenged hamsters, whereas Brand B facilitated the renal carrier state of the Leptospira organism In contrast the whole-cell vaccines developed from local strains of serovars Copenhageni and Mankarso, protected all hamsters tested from both clinical disease and renal carrier states (C) 2010 Elsevier Ltd All rights reserved.
引用
收藏
页码:5421 / 5426
页数:6
相关论文
共 45 条
[21]  
Koizumi N, 2005, J Postgrad Med, V51, P210
[22]   Leptospiral immunoglobulin-like proteins elicit protective immunity [J].
Koizumi, N ;
Watanabe, H .
VACCINE, 2004, 22 (11-12) :1545-1552
[23]  
Levett P N., 2004, Clinical and Applied Immunology Reviews, V4, P435, DOI 10.1016/j.cair.2004.08.001
[24]   Leptospirosis [J].
Levett, PN .
CLINICAL MICROBIOLOGY REVIEWS, 2001, 14 (02) :296-+
[25]   Detection of pathogenic leptospires by real-time quantitative PCR [J].
Levett, PN ;
Morey, RE ;
Galloway, RL ;
Turner, DE ;
Steigerwalt, AG ;
Mayer, LW .
JOURNAL OF MEDICAL MICROBIOLOGY, 2005, 54 (01) :45-49
[26]   Pulmonary Disease in Hamsters Infected with Leptospira interrogans: Histopathologic Findings and Cytokine mRNA Expressions [J].
Marinho, Marcia ;
Oliveira-Junior, Itamar Souza ;
Rodrigues Monteiro, Cristina Maria ;
Perri, Silvia Helena ;
Salomao, Reinaldo .
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2009, 80 (05) :832-836
[27]  
Marshall V, 1974, Mod Vet Pract, V55, P430
[28]   Control of immunologically crossreactive leptospiral infection by administration of lipopolysaccharides from a nonpathogenic strain of Leptospira biflexa [J].
Matsuo, K ;
Isogai, E ;
Araki, Y .
MICROBIOLOGY AND IMMUNOLOGY, 2000, 44 (11) :887-890
[29]  
Meeyam Tongkorn, 2006, Southeast Asian Journal of Tropical Medicine and Public Health, V37, P148
[30]   Reemerging leptospirosis, California [J].
Meites, E ;
Jay, MT ;
Deresinski, S ;
Shieh, WJ ;
Zaki, SR ;
Tompkins, L ;
Smith, DS .
EMERGING INFECTIOUS DISEASES, 2004, 10 (03) :406-412